## Amendments to the claims

The listing of claims will replace all prior versions, and listings, of claims in the application.

## **Listing of Claims**

Claims 1-40. (Canceled)

- 41. (New) A method of treating or preventing depression which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of didesmethylsibutramine, or a pharmaceutically acceptable salt, solvate, clathrate or prodrug thereof.
- 42. (New) The method of claim 41, wherein the didesmethylsibutramine is (R)-didesmethylsibutramine, (S)-didesmethylsibutramine or (R,S)-didesmethylsibutramine.
- 43. (New) The method of claim 41, wherein the amount of didesmethylsibutramine administered is from about 0.1 mg to 60 mg.
- 44. (New) The method of claim 43, wherein the amount of didesmethylsibutramine administered is from about 2 mg to 30 mg.
- 45. (New) The method of claim 44, wherein the amount of didesmethylsibutramine administered is from about 5 mg to 15 mg/day.
- 46. (New) The method of claim 41, wherein didesmethylsibutramine is administered orally, mucosally, rectally, parenterally, transdermally or subcutaneously.
- 47. (New) The method of claim 46, wherein didesmethylsibutramine is administered orally, mucosally or transdermally.
- 48. (New) The method of claim 41, which further comprises the administration of an additional pharmacologically active compound.
- 49. (New) The method of claim 48, wherein the additional pharmacologically active compound is a drug that affects the central nervous system, wherein the drug is: a

DC1: 358145.1

selective serotonin uptake inhibitor; a 5-HT agonist or antagonist; a hypnotic or a sedative; a drug useful in treating psychiatric disorder; a CNS stimulant; a dopamine receptor antagonist; an antimonic agent; an antipanic agent; a cardiovascular agent; an antiviral; an antibiotic; an antifungal; or an antineoplastic agent.

5 DC1: 358145.1